Biotoxtech Co., Ltd. (KOSDAQ:086040)
2,275.00
-30.00 (-1.30%)
At close: Sep 18, 2026
Biotoxtech Revenue
Biotoxtech had revenue of 14.46B KRW in the quarter ending June 30, 2026, with 50.29% growth. This brings the company's revenue in the last twelve months to 52.48B, up 20.88% year-over-year. In the year 2025, Biotoxtech had annual revenue of 47.02B with 13.73% growth.
Revenue (ttm)
52.48B
Revenue Growth
+20.88%
P/S Ratio
0.68
Revenue / Employee
279.13M
Employees
188
Market Cap
35.76B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 47.02B | 5.68B | 13.73% |
| Dec 31, 2024 | 41.34B | 8.71B | 26.69% |
| Dec 31, 2023 | 32.63B | -4.66B | -12.50% |
| Dec 31, 2022 | 37.29B | 4.57B | 13.98% |
| Dec 31, 2021 | 32.72B | 6.29B | 23.80% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Nara Mold & Die | 184.03B |
| Okong | 169.03B |
| BG T&A Co. | 144.65B |
| Seoulin Bioscience | 83.17B |
| EG Corporation | 66.55B |
| CNTUS Co.,Ltd | 62.50B |
| Kolmar BioTech | 40.30B |
| Catis. | 23.18B |